Vaccine versus variants: the battle rages

JOSEPH MCCORMICK, MD
SUSAN FISHER-HOCH, MD

Professors of Epidemiology
Brownsville Campus, UTHealth School of Public Health

8 strains of the coronavirus are circling the globe
CORONAVIRINAE

- Widespread among mammals in which it causes only mild respiratory or enteric disease
- Over 60 coronaviruses (CoVs) have been isolated from bats (BtCov)
- Bat reservoirs are large and highly mobile, and each species has its own unique BtCoV

- 2002 saw the first outbreak in humans of a BtCoV, this was Severe Acute Respiratory Syndrome (SARS) due to a new BtCoV (SARS-CoV-1)
- In 2014 a second distinct BtCoV was isolated in an outbreak of severe respiratory disease in humans in the Middle East (MERS-CoV)
In 2020, COVID-19 was the third leading cause of death in the U.S.*

PROVISIONAL 2020 DEATHS

1. Heart Disease 690K
2. All Cancers 598K
3. COVID-19 345K

* Provisional National Vital Statistics System (NVSS) death certificate data on underlying causes of death among U.S. residents in the United States during January–December 2020
DNA viruses: Herpes, CMV, smallpox, adenoviruses, chickenpox

Negative Strand RNA viruses: HIV, Polio, Influenza, Ebola, measles, mumps,

Positive Strand RNA viruses: SARS-CoV-2, Dengue, west Nile, Zika, rhinoviruses, rubella
How cells make protein from DNA

Key to virus replication

Cell Nucleus

Cell Cytoplasm

mRNA from Nucleus

Ribosome

mRNA from translation of mRNA

Peptide from translation of mRNA
Virus Targets for Vaccine development

RNA Of the Viral spike Protein is the target Of most vaccines

SARS-CoV-2 uses its spike to bind to the ACE2 receptor, allowing access into the cell.
The virus’s RNA is released into the cell. The cell reads the RNA and makes proteins.
The viral proteins are then assembled into new copies of the virus.
The copies are released and go on to infect more cells.
Basis of Moderna and Pfizer-BioNTech vaccine

Moderna’s vaccine will need to be refrigerated, and should be stable for up to six months when shipped and stored at –4°F (–20°C).
The Pfizer vaccine requires storage at -80°C.

NY Times
Viral Vector Vaccines

Vaccines that contain viruses engineered to carry coronavirus genes. Some viral vector vaccines enter cells and cause them to make viral proteins. Other viral vectors slowly replicate, carrying coronavirus proteins on their surface.

Johnson & Johnson

VACCINE NAME: Ad26.COV2.S
EFFICACY: 72% in United States, 64% in South Africa, 61% in Latin America
DOSE: 1 dose
TYPE: Muscle injection
STORAGE: Up to two years frozen at −4°F (−20°C), and up to three months refrigerated at 36–46°F (2–8°C).

AstraZeneca

VACCINE NAME: AZD1222 (also known as Covishield in India)
EFFICACY: 82.4% for doses separated by 12 weeks.
DOSE: 2 doses
TYPE: Muscle injection
STORAGE: Stable in refrigerator for at least 6 months

CanSinoBIO

VACCINE NAME: Convidecia (also known as Ad5-nCoV)
EFFICACY: 65.28%
DOSE: Single dose
TYPE: Muscle injection
STORAGE: Refrigerated

Sputnik V (also known as Gam-Covid-Vac)
EFFICACY: 91.6%
DOSE: 2 doses, 3 weeks apart
TYPE: Muscle injection
STORAGE: Freezer storage. Developing an alternative formulation that can be refrigerated.
The gene for the coronavirus spike protein put into another virus called Adenovirus 26.

- Adenoviruses are common viruses that typically cause colds or flu-like symptoms.
- The modified adenovirus can enter cells but can’t replicate inside them or cause illness.
- J&J vaccine comes out of decades of research on adenovirus-based vaccines.
- In July, the first one was approved for Ebola vaccine.
- DNA is not as fragile as RNA, and the adenovirus’s tough protein coat helps protect the genetic material inside.
- It can be stored at 36-46°F so much easier to distribute.
- It is a one dose vaccine.
Interactions of vaccinated cells and the virus

Activating B Cell
Matching Surface Proteins

B Cell
Vaccinated Cell

Helper T-Cell

Virus
Spikes
Antibodies to spike protein

Secreted Antibodies to Spike Protein

NY Times
Moderna, Pfizer, Johnson and Johnson and AstraZeneca vaccines now in full phase 4 application

Novavax protein vaccine in phase 3 trials

Inactivated whole virus vaccines from China and India are in Phase 4
Pfizer-BioNtech vaccine is manufactured almost identical to Moderna.

Cumulative incidence of Covid-19 among clinical trial participants

- People taking the Pfizer-BioNTech vaccine
- People taking a placebo

Weeks

NY Times
Cumulative incidence curves (1 minus the Kaplan–Meier risk) for the various outcomes are shown, starting from the day of administration of the first dose of vaccine. Shaded areas represent 95% confidence intervals. The number at risk at each time point and the cumulative number of events are also shown for each outcome. Graphs in which all data are shown with a y axis scale from 0 to 100 (along with the data shown, as here, on an expanded y axis) are provided in Figure S8 in the Supplementary Appendix.
<table>
<thead>
<tr>
<th>Efficacy End Point</th>
<th>BNT162b2</th>
<th>Placebo</th>
<th>Vaccine Efficacy, % (95% Credible Interval)§</th>
<th>Posterior Probability (Vaccine Efficacy &gt;30%)§</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of Cases</td>
<td>Surveillance Time (n)†</td>
<td>No. of Cases</td>
<td>Surveillance Time (n)†</td>
</tr>
<tr>
<td>Covid-19 occurrence at least 7 days after the second dose in participants without evidence of infection</td>
<td>(N=18,198)</td>
<td>8</td>
<td>162</td>
<td>2.214 (17,411)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(N=18,325)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Covid-19 occurrence at least 7 days after the second dose in participants with and those without evidence of infection</td>
<td>(N=19,965)</td>
<td>9</td>
<td>169</td>
<td>2.332 (18,559)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(N=20,172)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The total population without baseline infection was 36,523; total population including those with and those without prior evidence of infection was 40,137.
† The surveillance time is the total time in 1,000 person-years for the given end point across all participants within each group at risk for the end point. The time period for Covid-19 case accrual is from 7 days after the second dose to the end of the surveillance period.
‡ The credible interval for vaccine efficacy was calculated with the use of a beta-binomial model with prior beta (0.700102, 1) adjusted for the surveillance time.
§ Posterior probability was calculated with the use of a beta-binomial model with prior beta (0.700102, 1) adjusted for the surveillance time.
A record over 4 million doses were administered on April 10, 2021.
Distribution of vaccine in New York City
The map of vaccination counts per 10,000 population at census block group level

4080 people were included in this initial analysis but work is continuing
Maps of the census-tract cumulative COVID-19 case between March 8\textsuperscript{th} and December 12\textsuperscript{th}, 2020 (panel A), vaccination rate (by March 13\textsuperscript{th}, 2021) (panel B), social vulnerability index (panel C) and percentage of population with 65 years old and over (panel D).
### TABLE 2. Person-days, SARS-CoV-2 infections, and vaccine effectiveness among health care personnel, first responders, and other essential and frontline workers, by messenger RNA immunization status — eight U.S. locations, December 14, 2020–March 13, 2021

<table>
<thead>
<tr>
<th>COVID-19 immunization status</th>
<th>Person-days</th>
<th>No.</th>
<th>SARS-CoV-2 infections</th>
<th>Unadjusted vaccine effectiveness*</th>
<th>Adjusted vaccine effectiveness*¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unvaccinated</td>
<td>116,657</td>
<td>161</td>
<td>1.38</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Partially immunized</td>
<td>41,856</td>
<td>8</td>
<td>0.19</td>
<td>82 (62–91)</td>
<td>80 (59–90)</td>
</tr>
<tr>
<td>≥14 days after receiving first dose only¹</td>
<td>15,868</td>
<td>5</td>
<td>0.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥14 days after first dose through receipt of second dose</td>
<td>25,988</td>
<td>3</td>
<td>0.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fully immunized</td>
<td>78,902</td>
<td>3</td>
<td>0.04</td>
<td>91 (73–97)</td>
<td>90 (68–97)</td>
</tr>
</tbody>
</table>

| Abbreviations: CI = confidence interval; N/A = not applicable. |
* Vaccine effectiveness was estimated using a Cox proportional hazards model accounting for time-varying immunization status. |
¹ Hazard ratio is adjusted for study site. |
² Participants received first dose but had not received second dose by the end of the study period. |
Surveillance and detection of SARS-CoV-2 variants

- Globally the approach has been sporadic and unplanned
- Has depended mostly on resources and scientist initiative
- This is the pattern in the USA where discovery up to the end of last year is DESCRIBED AS SERENDIPITOUS
- ONLY IN THE UK WAS THE APPROACH SYSTEMATIC.
- Hence the identification of the B.1.1.7 in September associated with a cluster in Kent,
### SARS-CoV-2 variants

#### Variants of concern

<table>
<thead>
<tr>
<th>Lineage</th>
<th>Variant name</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.1.7</td>
<td>Variant of Concern 202012/01, or 501Y.V1</td>
<td>Emerged in Britain in December and is roughly 50 percent more infectious. Now detected in over 70 countries and 33 states.</td>
</tr>
<tr>
<td>B.1.351</td>
<td>501Y.V2</td>
<td>Emerged in South Africa in December. Reduces the effectiveness of some vaccines.</td>
</tr>
<tr>
<td>P.1</td>
<td>501Y.V3</td>
<td>Emerged in Brazil in late 2020. Has mutations similar to B.1.351.</td>
</tr>
</tbody>
</table>

#### Mutations that may help the coronavirus spread

<table>
<thead>
<tr>
<th>Lineage</th>
<th>Mutation</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1</td>
<td>D614G</td>
<td>Appeared in early 2020 and spread around the world.</td>
</tr>
<tr>
<td>Several</td>
<td>N501Y</td>
<td>A defining mutation in several lineages, including B.1.1.7, B.1.351 and P.1. Helps the virus bind more tightly to human cells.</td>
</tr>
<tr>
<td>Several</td>
<td>E484K</td>
<td>Appears in several lineages. May help the virus avoid some kinds of antibodies.</td>
</tr>
<tr>
<td>Several</td>
<td>L452R</td>
<td>Increasingly common in California, but not yet shown to be more infectious.</td>
</tr>
</tbody>
</table>

#### Lineage-specific variants

<table>
<thead>
<tr>
<th>Lineage</th>
<th>Variant name</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.1.427, CAL.20C</td>
<td></td>
<td>Carries the L452R mutation. Common in California, but not yet shown to be more infectious.</td>
</tr>
</tbody>
</table>
KEY MUTATIONS IN B.1.1.7

Mutations in the spike protein include:

— **N501Y**, which helps the virus latch on more tightly to human cells. But the mutation is not likely to help the virus evade current vaccines.

— **P681H**, which may help infected cells create new spike proteins more efficiently.

— The **H69–V70** and **Y144/145** deletions, which alter the shape of the spike and may help it evade some antibodies.
KEY MUTATIONS IN B.1.351

Mutations near the tip of the spike protein include:

— **N501Y**, which helps the virus latch on more tightly to human cells. This mutation also appears in the B.1.1.7 and P1 lineages.

— **K417N**, which also helps the virus bind more tightly to human cells.

— **E484K**, which may help the virus evade some kinds of antibodies.
KEY MUTATIONS IN P.1

Key mutations in the spike protein are similar to those in the B.1.351 lineage, although they arose independently:

— **N501Y**, which helps the virus latch on more tightly to human cells. This mutation also appears in the B.1.1.7 and B.1.351 lineages.

— **K417T**, which is the same site as the K417N mutation in the B.1.351 lineage. It may also help the virus latch on tighter.

— **E484K**, which may help the virus evade some kinds of antibodies.
Neutralizing Activity of BNT162b2-Elicited Serum

March 8, 2021
DOI: 10.1056/NEJMmc2102017

Serum Neutralization of Variant Strains of SARS-CoV-2 after the Second Dose of BNT162b2 Vaccine.
Calculated proportions of adverse pregnancy and neonatal outcomes were similar in incidences to those pre COVID-19 pandemic.
Figure S2: Serial dilution of patient sera in IgG anti-PF4/polyanion ELISA.
# Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

## Table 1. Pregnancy Complications, Perinatal Events, and Neonatal Morbidities Among Women With and Without COVID-19 Diagnosis and Their Newborns

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%)</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Women with COVID-19 diagnosis (n = 706)</td>
<td>Women without COVID-19 diagnosis (n = 1424)</td>
</tr>
<tr>
<td>Maternal morbidity and mortality index*</td>
<td>225 (31.9)</td>
<td>296 (20.8)</td>
</tr>
<tr>
<td>Vaginal bleeding</td>
<td>44 (6.2)</td>
<td>87 (6.1)</td>
</tr>
<tr>
<td>Pregnancy-induced hypertension</td>
<td>58 (8.2)</td>
<td>80 (5.6)</td>
</tr>
<tr>
<td>Preeclampsia/eclampsia/HELLP</td>
<td>59 (8.4)</td>
<td>63 (4.4)</td>
</tr>
<tr>
<td>Hemoglobin level &lt;10 g/dL at &gt;27 wk gestation</td>
<td>130 (18.4)</td>
<td>228 (16.0)</td>
</tr>
<tr>
<td>Preterm labor</td>
<td>52 (7.4)</td>
<td>88 (6.2)</td>
</tr>
<tr>
<td>Infections requiring antibiotics</td>
<td>25 (3.6)</td>
<td>16 (1.1)</td>
</tr>
<tr>
<td>Admitted to ICU</td>
<td>59 (8.4)</td>
<td>23 (1.6)</td>
</tr>
<tr>
<td>Time in ICU, mean (SD), d</td>
<td>7.3 (7.8)</td>
<td>2.0 (1.7)</td>
</tr>
<tr>
<td>Referred for higher dependency care</td>
<td>6 (0.9)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Maternal death</td>
<td>11 (1.6)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Fetal distress</td>
<td>87 (12.3)</td>
<td>120 (8.4)</td>
</tr>
</tbody>
</table>
Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

<table>
<thead>
<tr>
<th>Outcome</th>
<th>With COVID-19 (n)</th>
<th>Without COVID-19 (n)</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneous initiation of labor</td>
<td>333 (47.2)</td>
<td>793 (55.7)</td>
<td>0.85 (0.77 to 0.93)</td>
</tr>
<tr>
<td>Induced labor</td>
<td>157 (22.3)</td>
<td>320 (22.5)</td>
<td>0.99 (0.84 to 1.18)</td>
</tr>
<tr>
<td>Cesarean delivery</td>
<td>346 (49.0)</td>
<td>547 (38.4)</td>
<td>1.28 (1.16 to 1.40)</td>
</tr>
<tr>
<td>Prelabor rupture of membranes</td>
<td>114 (16.1)</td>
<td>262 (18.4)</td>
<td>0.87 (0.71 to 1.07)</td>
</tr>
<tr>
<td>Gestational age at birth, mean (SD), wk</td>
<td>37.9 (3.3)</td>
<td>38.5 (3.1)</td>
<td>−0.61 (−0.90 to −0.32)</td>
</tr>
<tr>
<td>Preterm birth (&lt;37 wk gestation)</td>
<td>159 (22.5)</td>
<td>194 (13.6)</td>
<td>1.59 (1.30 to 1.94)</td>
</tr>
<tr>
<td>Spontaneous preterm birth</td>
<td>27 (3.8)</td>
<td>66 (4.6)</td>
<td>0.81 (0.52 to 1.27)</td>
</tr>
<tr>
<td>Medically indicated preterm birth</td>
<td>133 (18.8)</td>
<td>127 (8.9)</td>
<td>1.97 (1.56 to 2.51)</td>
</tr>
<tr>
<td>Birth weight, mean (SD), kg</td>
<td>2.96 (0.70)</td>
<td>3.07 (0.68)</td>
<td>−0.11 (−0.18 to −0.04)</td>
</tr>
<tr>
<td>Male</td>
<td>353 (50.0)</td>
<td>749 (52.6)</td>
<td>0.95 (0.87 to 1.04)</td>
</tr>
<tr>
<td>Female</td>
<td>353 (50.0)</td>
<td>675 (47.6)</td>
<td>1.06 (0.96 to 1.16)</td>
</tr>
<tr>
<td>Low birth weight (&lt;2500 g)</td>
<td>145 (20.5)</td>
<td>181 (12.7)</td>
<td>1.58 (1.29 to 1.94)</td>
</tr>
<tr>
<td>Small for gestational age (&lt;10th centile)</td>
<td>97 (13.7)</td>
<td>181 (12.7)</td>
<td>1.03 (0.81 to 1.31)</td>
</tr>
<tr>
<td>Exclusive breastfeeding at discharge</td>
<td>378 (53.5)</td>
<td>953 (66.9)</td>
<td>0.80 (0.74 to 0.87)</td>
</tr>
<tr>
<td>Any breastfeeding at discharge</td>
<td>588 (83.3)</td>
<td>1290 (90.6)</td>
<td>0.92 (0.88 to 0.96)</td>
</tr>
</tbody>
</table>

**SNMI**

- SNMI: 44 (6.2) vs. 33 (2.3), 2.66 (1.69 to 4.18)
- Severe perinatal morbidity and mortality index: 120 (17.0) vs. 113 (7.9), 2.14 (1.66 to 2.75)
Beyond 30 days post acute COVID-19 patients exhibit higher risk of death and health resource utilization:

- Respiratory system
- Nervous system system
- Neurocognitive disorders,
- Cardiovascular disorders,
- Gastrointestinal disorders
- Malaise
- Fatigue
- Musculoskeletal pain
- Anemia

Increased use of opioids and non-opioids, antidepressants, anxiolytics, antihypertensives and oral hypoglycemics and multiple laboratory abnormalities
Coronaviruses are highly mutational that promotes their capacity to ‘species jump’. When they do, the results can be unexpected. The original host may have no disease, the new host very sick.
**METHODS**

Archival sewage samples:
- Pre-epidemic period: 40 samples (October 2019 - February 2020)
- Non-epidemic period: 24 samples (September 2018 - June 2019)

- Sample concentration (WHO, 2003, with modifications)
- Viral nucleic acids extraction with magnetic silica beads
- Real-time RT-PCR (newly designed assay) + Nested RT-PCR and sequencing

**RESULTS**

First occurrence of SARS-CoV-2 in sewage:

<table>
<thead>
<tr>
<th>City</th>
<th>Date of sampling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milan</td>
<td>December 18, 2019</td>
</tr>
<tr>
<td>Turin</td>
<td>December 18, 2019</td>
</tr>
<tr>
<td>Bologna</td>
<td>January 29, 2020</td>
</tr>
</tbody>
</table>

- Agreement between the two assays: 65.0% (26/40 paired results)
- Virus concentration: from <LOD to $5.6 \times 10^4$ g.c./L; most of the samples were below the analytical LOQ

**CONCLUSIONS**

- SARS-CoV-2 has been circulating in northern Italy since December 2019
- WBE could contribute to the early detection of a possible second wave of infection
This is what the variants are doing
Sharp rise in global cases is causing concern

More than 5.2 million new Covid-19 cases were recorded around the world last week, bringing the total to more than 142 million cases since the start of the pandemic.
India’s second wave

India has reported an average of over 230,000 new Covid-19 cases each day in the past week, bringing total cases to over 15 million as a second wave sweeps the country.

B.1.617: ‘double variant’
B.1.1.7: ‘UK variant’
The coronavirus pandemic has left more than 3 million dead around the world. Cases are rising rapidly. In India this surge is not a wave, but a wall.
Oxygen is in such short supply that tankers are hauling it in from other states. Patients still face a scramble to find available hospital beds.
SUMMARY

• This is a bad, bad virus, but is vaccine preventable.
• We have vaccines that are both safe & effective
• Most vaccine appear so far effective against all variants
• Serious vaccine side effects are extremely rare
• Protection following vaccination is solid and appears to persist
• Vaccines may confer some immunity to infection thus limiting spread at least by lowering virus loads
• Immunity following infection is not solid, but is better with vaccine
• Distribution in Western countries is progressing well

• Problems remain
  • Many parts of the world have insufficient vaccine and delivery systems and continue to be devastated.
  • Until this is addressed the virus can mutate and spread
  • Vaccine access & hesitancy are real threats to global herd immunity.
  • Political and inequality issues need to be addressed.